Key result
Elevated mean FAI Score (90th centile vs bottom quartile) in patients without SMuRFs predicted MACE (HR 4.4, 95% CI 3.5-5.5) and CV mortality (HR 12.6, 95% CI 7.2-21.9; both p<0.001).
Why the study?
Many patients experience coronary events without standard modifiable CV risk factors (SMuRFs), highlighting limitations of traditional risk stratification. The prognostic value of CCTA-derived perivascular fat attenuation index (FAI) Score as a marker of coronary inflammation in individuals without SMuRFs required exploration.
Does coronary inflammation quantified by the CCTA-derived perivascular fat attenuation index (FAI) Score predict major adverse cardiovascular events and cardiovascular mortality in individuals without standard modifiable cardiovascular risk factors (SMuRFs)?
Cohort (n=73,689)
Yes
Does coronary inflammation quantified by the CCTA-derived perivascular fat attenuation index (FAI) Score predict major adverse cardiovascular events and cardiovascular mortality in individuals without standard modifiable cardiovascular risk factors (SMuRFs)?
Coronary inflammation quantified by CCTA-derived FAI Score strongly and independently predicts cardiovascular mortality and MACE in patients without standard modifiable risk factors, supporting the use of vascular inflammation imaging biomarkers to improve risk stratification beyond traditional risk factors.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“The strength of these associations was progressively attenuated with increasing SMuRF burden even after adjustment for CAD severity, suggesting that coronary inflammation plays a proportionally greater role in risk among SMuRFless individuals.”
Elevated FAI Score was associated with high CV mortality in SMuRF-negative patients; leaves open whether it should guide therapy.
Background Standard modifiable cardiovascular (CV) risk factors (SMuRFs), including diabetes, hypertension, hyperlipidaemia, smoking and obesity, form the cornerstone of contemporary CV risk prediction. However, a substantial proportion of patients experience coronary events in the absence of these risk factors, highlighting limitations of traditional risk stratification. Coronary inflammation is a key driver of atherosclerosis and plaque instability and may represent a mechanistic pathway underlying this residual risk in patients without SMuRFs. Purpose To explore the prognostic value of coronary inflammation, quantified by the perivascular fat attenuation index (FAI) Score measured using coronary CT angiography (CCTA), in individuals without SMuRFs. Methods This multicentre longitudinal cohort study included 73,689 consecutive patients undergoing clinically indicated CCTA, enrolled in the Oxford Risk Factors and Non-invasive imaging (ORFAN) study. Patients were stratified according to SMuRF burden (0 to ≥3). Coronary inflammation was quantified using mean FAI Score (a CCTA-derived biomarker of coronary inflammation). Major adverse cardiovascular events (MACE) were defined as myocardial infarction (MI), new heart failure, or CV death. Cox proportional hazards models were fitted to estimate the hazard ratios (HR) and 95% confidence intervals (CI) for clinical outcomes. The prognostic value of mean FAI Scores (the mean of the FAI Scores in all three coronary arteries) was evaluated in SMuRFless and SMuRF-positive individuals. Results Over a median follow-up of 6.6 years (IQR 5.1-9.1), patients without SMuRFs [n=13,294 (18%)] accounted for 722 (8.9%) of the 8,125 total MACE events and 191 (7.8%) of the total 2,454 CV deaths. Increased mean FAI Scores were predictive of CV mortality (HR 12.6, 95% CI (7.2-21.9), p<0.001) [A] and MACE (HR 4.4, 95% CI (3.5-5.5), p<0.001) [B] comparing the mean FAI Score in the 90th centile versus bottom quartile for patients without SMuRFs. The association between mean FAI Score and CV death, MI, and ischaemic stroke was strongest in SMuRFless individuals compared to those with SMuRFs[C]. For each standard deviation increase in mean FAI Score, the HR was 1.42, 95% CI (1.34–1.50) for CV death, 1.16, 95% CI (1.05–1.26) for MI, and 1.27, 95% CI (1.16–1.39) for ischaemic stroke [D]. The strength of these associations was progressively attenuated with increasing SMuRF burden even after adjustment for CAD severity, suggesting that coronary inflammation plays a proportionally greater role in risk among SMuRFless individuals. Conclusions Coronary inflammation, quantified by FAI Score, provides independent prognostic information in patients without SMuRFs. These findings highlight the limitations of SMuRF-based risk assessment and support further evaluation of imaging biomarkers of vascular inflammation to enable more precise CV risk stratification and earlier preventive intervention.Picture 1
No takes yet. Share an insight, caveat, or question.
Eveson et al. (2026) conducted a cohort in Suspected coronary artery disease / Cardiovascular risk assessment (including 13,294 without standard modifiable risk factors) (n=73,689). Elevated coronary inflammation (mean perivascular fat attenuation index [FAI] Score in the 90th centile) vs. Bottom quartile of mean FAI Score (in patients without SMuRFs) was evaluated on Major adverse cardiovascular events (MACE: myocardial infarction, new heart failure, or cardiovascular death) (HR 4.4, 95% CI 3.5-5.5, p=<0.001). Elevated mean FAI Score (90th centile vs bottom quartile) in patients without SMuRFs predicted MACE (HR 4.4, 95% CI 3.5-5.5) and CV mortality (HR 12.6, 95% CI 7.2-21.9; both p<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: